diabetic retinopathy
DESCRIPTION
Opthalmologists view.TRANSCRIPT
![Page 1: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/1.jpg)
DIABETIC RETINOPATHY
![Page 2: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/2.jpg)
![Page 3: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/3.jpg)
![Page 4: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/4.jpg)
Progressive dysfunction of the retinal blood vessels caused by chronic hyperglycaemia.
Definition
![Page 5: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/5.jpg)
1. Hyperglycaemia Duration of diabetes - 50% develop DR after 10 yrs- 70 % after 20 yrs- 90 % after 30 yrs 2. Hypertension 3. Hyperlipidaemia4. More in females than males5. Pregnancy may accelerate DR6. Smoking, Obesity, Anaemia7. Poor metabolic control8. Hereditary – more on proliferative DR
Risk Factors
![Page 6: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/6.jpg)
![Page 7: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/7.jpg)
![Page 8: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/8.jpg)
![Page 9: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/9.jpg)
![Page 10: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/10.jpg)
![Page 11: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/11.jpg)
Classification of Diabetic Retinopathy
• Non-proliferative diabetic retinopathy
I. Mild nonproliferative retinopathyII. Moderate nonproliferative retinopathyIII.Severe nonproliferative retinopathyIV.Very severe nonproliferative retinopathy
• Proliferative diabetic retinopathy
• Diabetic maculopathy
• Advanced diabetic eye disease
![Page 12: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/12.jpg)
No retinopathy
![Page 13: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/13.jpg)
I. Mild nonproliferative retinopathy
• Atleast one microaneurysm or intraretinal haemorrhage
• Hard/ Soft exduates may or may not be present
![Page 14: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/14.jpg)
![Page 15: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/15.jpg)
II. Moderate nonproliferative retinopathy
• Micro aneurysms / intraretinal haemorrhages in 2 or 3 quadrants
• Early mild IRMA Intra retinal Microvascular abnormalities
• Hard / Soft exudates may or may not be present
![Page 16: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/16.jpg)
![Page 17: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/17.jpg)
![Page 18: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/18.jpg)
III. Severe nonproliferative retinopathy
• Four quadrants of severe micro aneurysms / intraretinal haemorrhages
• Two quadrants of venous bleeding
• One quadrant of IRMA changes
Any one of the following :
![Page 19: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/19.jpg)
![Page 20: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/20.jpg)
![Page 21: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/21.jpg)
IV. Very severe nonproliferative retinopathy
• Four quadrants of severe micro aneurysms / intraretinal haemorrhages
• Two quadrants of venous bleeding
• One quadrant of IRMA changes
Any two of the following :
![Page 22: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/22.jpg)
Proliferative diabetic retinopathy
PDR
PDR without HRC PDR with HRC
NVD ¼ to 1/3 of disc area with or without VH or PRH
NVD < ¼ disc area with VH or PRH
NVD < ¼ disc area with VH or PRH
![Page 23: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/23.jpg)
![Page 24: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/24.jpg)
Extensive vitreous haemorrhage obscuring most of fundus (white circle)
![Page 25: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/25.jpg)
![Page 26: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/26.jpg)
![Page 27: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/27.jpg)
![Page 28: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/28.jpg)
![Page 29: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/29.jpg)
Diabetic Maculopathy
On Slit lamp examination with 90D lens :
1. Thickening of retina at or within 500 micron of the centre of fovea
2. Hard exudates at or within 500 micron of the centre of fovea associated with adjacent retinal thickening
3. Development of a zone of retinal thickening one disc diameter or larger in size, at least a part of which is within one disc diameter of foveal centre.
![Page 30: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/30.jpg)
![Page 31: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/31.jpg)
Maculopathy within 1 disc diameter of the fovea.
![Page 32: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/32.jpg)
Advanced diabetic eye disease
1. Persistent vitreous haemorrhage
2. Tractional retinal detachment
3. Neovascular glaucoma
![Page 33: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/33.jpg)
![Page 34: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/34.jpg)
Investigations
1. Urine examination2. Blood sugar estimation3. 24 hour urinary protein4. Renal function tests5. Lipid profile6. Haemogram7. Glycosylated Haemoglobin (HbA1C)8. Fundus Fluorescein angiography – to
elucidate areas of neovascularisation, leakage and capillary nonperfusion
9. Optical Coherence Tomography to study detailed structural changes in diabetic maculopathy
![Page 35: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/35.jpg)
Prevention1.Primary Prevention –
Strict glycemic control, Blood pressure control, correction of dyslipidaemia, control of associated anaemia, control of hypoproteinemia
2.Secondary Prevention – Annual eye exams
3.Tertiary Prevention – Retinal laser photocoagulation , Vitrectomy
![Page 36: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/36.jpg)
Treatment of Diabetic Retinopathy
1. Anti – vascular endothelial growth factors
2. Others under evaluation – Protein Kinase C inhibitors, Aldose reductase, ACE inhibitors, Antioxidants such as vitamin E
3. Role of intravitreal steroids – Flucinolone acetonide intravitreal implant, Inj. Triamcinolone intravitreal
![Page 37: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/37.jpg)
Laser Photocoagulation
![Page 38: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/38.jpg)
![Page 39: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/39.jpg)
![Page 40: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/40.jpg)
Vitrectomy
![Page 41: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/41.jpg)
![Page 42: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/42.jpg)
September 16, 2014
Eylea Granted Breakthrough Therapy for Diabetic RetinopathyFood and Drug Administration (FDA) has granted Eylea (afilbercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
Eylea is a vascular endothelial growth factor (VEGF) inhibitor designed to block the growth of new blood vessels and decreases vascular permeability in the eye by blocking VEGF-A and placental growth factor (PlGF), two growth factors involved in angiogenesis.
Eylea helps prevent VEGF-A and PlGF from interacting with their natural VEGF receptors as shown in preclinical studies.
Eylea is already approved for the treatment of neovascular (wet) age-related macular degeneration (AMD) and macular edema following central retinal vein occlusion (CRVO).
Latest Treatment modalities for Diabetic Retinopathy
![Page 43: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/43.jpg)
Human trials are set to begin for a new medication, currently called KVD001, which treats diabetic macular edema, a form of diabetic retinopathy.
Human trials begin for promising diabetic retinopathy treatmentFri, 05 Sep 2014
KVD001 is an intravitreal plasma kallikrein inhibitor drug that is given byinjection into the eye. Whilst injections into the eye may sound painful, in practice they are not as eye-watering as they sound.
There is currently only one medication, Lucentis, has been officially licensed for treatment of diabetic macular edema. Having another medication such as KVD001 would give doctors more choice over which treatment to give and, because it works in a different way to Lucentis, it means that it could help save thesight of people for whom Lucentis is not effective.
KVD001 has been developed by KalVista Pharmaceuticals, a company in Hampshire. The clinical trials, which will be run across five different centres within the United States, are being funded by the type 1 diabetes charity, the JDRF.
![Page 44: Diabetic retinopathy](https://reader036.vdocument.in/reader036/viewer/2022062406/5589eee2d8b42add0d8b46c5/html5/thumbnails/44.jpg)
Conclusion
Diabetic Retinopathy is preventable through strict glycemic control and annual dialated eye exams by an opthalmologist.